Active — Not RecruitingNot Applicable

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

United States13 participantsStarted 2020-11-03

Plain-language summary

Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects who received SB-318 under Study Protocol SB-318-1502, SB-913 under Study Protocol SB-913-1602, or SB-FIX under Study Protocol SB-FIX-1501
✓. Subjects who have provided consent to participate in the LTFU study.

Exclusion criteria

✕. Unable to comply with study visit schedule or study visit procedures.
✕. Any other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study.

What they're measuring

Long-term safety

Timeframe: 10 years

Trial details

NCT IDNCT04628871

SponsorSangamo Therapeutics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-01-01

View on ClinicalTrials.gov More Hemophilia B trials